A5018419311- Atrial Fibrillation Management and Outcomes
- Blood Pressure and Hypertension Studies
- Heart Failure Treatment and Management
- Antiplatelet Therapy and Cardiovascular Diseases
- Acute Myocardial Infarction Research
- Cardiovascular Function and Risk Factors
- Health Systems, Economic Evaluations, Quality of Life
- Venous Thromboembolism Diagnosis and Management
- Nutritional Studies and Diet
- Global Public Health Policies and Epidemiology
- Cardiac electrophysiology and arrhythmias
- Cardiac, Anesthesia and Surgical Outcomes
- Lipoproteins and Cardiovascular Health
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Cardiac Arrhythmias and Treatments
- Cardiac Imaging and Diagnostics
- Cardiac pacing and defibrillation studies
- Cardiovascular Health and Risk Factors
- Obesity, Physical Activity, Diet
- Sodium Intake and Health
- Acute Ischemic Stroke Management
- Cardiac Health and Mental Health
- Diabetes Treatment and Management
- Coronary Interventions and Diagnostics
- Health disparities and outcomes
Population Health Research Institute
2016-2025
McMaster University
2016-2025
Hamilton Health Sciences
2016-2025
Universitas Muhammadiyah Jakarta
2025
Impact
2017-2024
Universidad Autónoma de Madrid
2024
Radboud University Medical Center
2024
Christ Hospital
2024
Health Net
2024
Radboud University Nijmegen
2024
Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases hemorrhage and is difficult to use. Dabigatran a new oral direct thrombin inhibitor.
Angiotensin-converting–enzyme inhibitors improve the outcome among patients with left ventricular dysfunction, whether or not they have heart failure. We assessed role of an angiotensin-converting–enzyme inhibitor, ramipril, in who were at high risk for cardiovascular events but did dysfunction
Despite current treatments, patients who have acute coronary syndromes without ST-segment elevation high rates of major vascular events. We evaluated the efficacy and safety antiplatelet agent clopidogrel when given with aspirin in such patients.
It is not known whether the treatment of patients with asymptomatic left ventricular dysfunction reduces mortality and morbidity. We studied effect an angiotensin-converting—enzyme inhibitor, enalapril, on total from cardiovascular causes, development heart failure, hospitalization for failure among ejection fractions 0.35 or less who were receiving drug failure.
Vitamin K antagonists have been shown to prevent stroke in patients with atrial fibrillation. However, many are not suitable candidates for or unwilling receive vitamin antagonist therapy, and these a high risk of stroke. Apixaban, novel factor Xa inhibitor, may be an alternative treatment such patients.In double-blind study, we randomly assigned 5599 fibrillation who were at increased whom therapy was unsuitable apixaban (at dose 5 mg twice daily) aspirin (81 324 per day), determine whether...
Vitamin K antagonists reduce the risk of stroke in patients with atrial fibrillation but are considered unsuitable many patients, who usually receive aspirin instead. We investigated hypothesis that addition clopidogrel to would vascular events fibrillation.
We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than for secondary cardiovascular prevention.In this double-blind trial, we randomly assigned 27,395 participants stable atherosclerotic vascular disease to receive (2.5 mg twice daily) plus (100 once daily), (5 daily). The primary outcome was a composite of death, stroke, myocardial infarction. study stopped superiority the rivaroxaban-plus-aspirin group after mean follow-up 23 months.The occurred...
Observational and experimental studies suggest that the amount of vitamin E ingested in food supplements is associated with a lower risk coronary heart disease atherosclerosis.